Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Mortality
Ventilation
Hospitalization
Serious outcomes
Cases
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
Outcomes in COVID-19 paxlovid studies
Outcomes in paxlovid studies. Pfizer has denied access to Paxlovid for an independent RCT.
0 0.5 1 1.5+ All studies 54% 5 9,853 Improvement, Studies, Patients Relative Risk Mortality 81% 2 7,028 Ventilation 31% 1 4,943 Hospitalization 44% 4 7,882 Cases 37% 1 1,971 Viral clearance 20% 1 4,943 RCTs 65% 3 4,910 Peer-reviewed 96% 1 2,085 Prophylaxis 37% 1 1,971 Early 63% 3 2,939 Late 68% 1 4,943 Paxlovid for COVID-19 c19early.com/pl May 2022 Favorspaxlovid Favorscontrol
0 0.5 1 1.5+ ALL STUDIES MORTALITY VENTILATION HOSPITALIZATION CASES VIRAL CLEARANCE RANDOMIZED CONTROLLED TRIALS PEER-REVIEWED All Prophylaxis Early Late Paxlovid for COVID-19 C19EARLY.COM/PL MAY 2022
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pfizer (DB RCT) 70% 0.30 [0.08-1.08] hosp. 3/428 10/426 Improvement, RR [CI] Treatment Control Hammond (DB RCT) 96% 0.04 [0.00-0.68] death 0/1,039 12/1,046 Yip (PSW) 19% 0.81 [0.47-1.39] death/ICU Tau​2 = 0.80, I​2 = 66.9%, p = 0.12 Early treatment 63% 0.37 [0.10-1.32] 3/1,467 22/1,472 63% improvement Wong (PSM) 68% 0.32 [0.23-0.45] death 991 (n) 3,952 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Late treatment 68% 0.32 [0.23-0.45] 0/991 0/3,952 68% improvement Pfizer (DB RCT) 37% 0.63 [0.40-1.00] cases 986 (n) 985 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.05 Prophylaxis 37% 0.63 [0.40-1.00] 0/986 0/985 37% improvement All studies 54% 0.46 [0.26-0.80] 3/3,444 22/6,409 54% improvement 5 paxlovid COVID-19 studies c19early.com/pl May 2022 Tau​2 = 0.24, I​2 = 74.9%, p = 0.006 Effect extraction pre-specified(most serious outcome) Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hammond (DB RCT) 96% 0.04 [0.00-0.68] 0/1,039 12/1,046 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.025 Early treatment 96% 0.04 [0.00-0.68] 0/1,039 12/1,046 96% improvement Wong (PSM) 68% 0.32 [0.23-0.45] 991 (n) 3,952 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Late treatment 68% 0.32 [0.23-0.45] 0/991 0/3,952 68% improvement All studies 81% 0.19 [0.03-1.11] 0/2,030 12/4,998 81% improvement 2 paxlovid COVID-19 mortality results c19early.com/pl May 2022 Tau​2 = 1.10, I​2 = 51.1%, p = 0.065 Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wong (PSM) 31% 0.69 [0.29-1.65] 991 (n) 3,952 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.41 Late treatment 31% 0.69 [0.29-1.65] 0/991 0/3,952 31% improvement All studies 31% 0.69 [0.29-1.65] 0/991 0/3,952 31% improvement 1 paxlovid COVID-19 mechanical ventilation result c19early.com/pl May 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.41 Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pfizer (DB RCT) 70% 0.30 [0.08-1.08] hosp. 3/428 10/426 Improvement, RR [CI] Treatment Control Hammond (DB RCT) 88% 0.12 [0.06-0.26] hosp. 8/1,039 65/1,046 Yip (PSW) 21% 0.79 [0.65-0.95] hosp. Tau​2 = 1.29, I​2 = 92.2%, p = 0.1 Early treatment 68% 0.32 [0.08-1.25] 11/1,467 75/1,472 68% improvement Wong (PSM) 7% 0.93 [0.87-1.00] hosp. time 991 (n) 3,952 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.039 Late treatment 7% 0.93 [0.87-1.00] 0/991 0/3,952 7% improvement All studies 44% 0.56 [0.37-0.85] 11/2,458 75/5,424 44% improvement 4 paxlovid COVID-19 hospitalization results c19early.com/pl May 2022 Tau​2 = 0.11, I​2 = 91.4%, p = 0.0062 Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pfizer (DB RCT) 70% 0.30 [0.08-1.08] hosp. 3/428 10/426 Improvement, RR [CI] Treatment Control Hammond (DB RCT) 96% 0.04 [0.00-0.68] death 0/1,039 12/1,046 Yip (PSW) 19% 0.81 [0.47-1.39] death/ICU Tau​2 = 0.80, I​2 = 66.9%, p = 0.12 Early treatment 63% 0.37 [0.10-1.32] 3/1,467 22/1,472 63% improvement Wong (PSM) 68% 0.32 [0.23-0.45] death 991 (n) 3,952 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Late treatment 68% 0.32 [0.23-0.45] 0/991 0/3,952 68% improvement All studies 61% 0.39 [0.18-0.84] 3/2,458 22/5,424 61% improvement 4 paxlovid COVID-19 serious outcomes c19early.com/pl May 2022 Tau​2 = 0.38, I​2 = 78.6%, p = 0.016 Effect extraction pre-specified(most serious outcome) Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pfizer (DB RCT) 37% 0.63 [0.40-1.00] cases 986 (n) 985 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.05 Prophylaxis 37% 0.63 [0.40-1.00] 0/986 0/985 37% improvement All studies 37% 0.63 [0.40-1.00] 0/986 0/985 37% improvement 1 paxlovid COVID-19 case result c19early.com/pl May 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.05 Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wong (PSM) 20% 0.80 [0.67-0.96] viral+ 991 (n) 3,952 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.017 Late treatment 20% 0.80 [0.67-0.96] 0/991 0/3,952 20% improvement All studies 20% 0.80 [0.67-0.96] 0/991 0/3,952 20% improvement 1 paxlovid COVID-19 viral clearance result c19early.com/pl May 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.017 Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pfizer (DB RCT) 70% 0.30 [0.08-1.08] hosp. 3/428 10/426 Improvement, RR [CI] Treatment Control Hammond (DB RCT) 96% 0.04 [0.00-0.68] death 0/1,039 12/1,046 Tau​2 = 0.76, I​2 = 37.8%, p = 0.049 Early treatment 83% 0.17 [0.03-0.99] 3/1,467 22/1,472 83% improvement Pfizer (DB RCT) 37% 0.63 [0.40-1.00] cases 986 (n) 985 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.05 Prophylaxis 37% 0.63 [0.40-1.00] 0/986 0/985 37% improvement All studies 65% 0.35 [0.12-1.05] 3/2,453 22/2,457 65% improvement 3 paxlovid COVID-19 Randomized Controlled Trials c19early.com/pl May 2022 Tau​2 = 0.50, I​2 = 55.5%, p = 0.061 Effect extraction pre-specified(most serious outcome) Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hammond (DB RCT) 96% 0.04 [0.00-0.68] 0/1,039 12/1,046 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.025 Early treatment 96% 0.04 [0.00-0.68] 0/1,039 12/1,046 96% improvement All studies 96% 0.04 [0.00-0.68] 0/1,039 12/1,046 96% improvement 1 paxlovid COVID-19 RCT mortality result c19early.com/pl May 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.025 Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hammond (DB RCT) 96% 0.04 [0.00-0.68] death 0/1,039 12/1,046 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.025 Early treatment 96% 0.04 [0.00-0.68] 0/1,039 12/1,046 96% improvement All studies 96% 0.04 [0.00-0.68] 0/1,039 12/1,046 96% improvement 1 paxlovid COVID-19 peer reviewed trials c19early.com/pl May 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.025 Effect extraction pre-specified(most serious outcome) Favors paxlovid Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pfizer (DB RCT) 70% 0.30 [0.08-1.08] hosp. 3/428 10/426 Improvement, RR [CI] Treatment Control Hammond (DB RCT) 96% 0.04 [0.00-0.68] death 0/1,039 12/1,046 Hammond (DB RCT) 95% 0.05 [0.00-0.89] death 0/697 9/682 Hammond (DB RCT) 88% 0.12 [0.06-0.26] hosp. 8/1,039 65/1,046 Hammond (DB RCT) 89% 0.11 [0.04-0.28] hosp. 5/697 44/682 Yip (PSW) 19% 0.81 [0.47-1.39] death/ICU Yip (PSW) 21% 0.79 [0.65-0.95] hosp. Wong (PSM) 68% 0.32 [0.23-0.45] death 991 (n) 3,952 (n) Wong (PSM) 31% 0.69 [0.29-1.65] ventilation 991 (n) 3,952 (n) Wong (PSM) 67% 0.33 [0.24-0.46] death/ICU 991 (n) 3,952 (n) Wong (PSM) 7% 0.93 [0.87-1.00] hosp. time 991 (n) 3,952 (n) Wong (PSM) 20% 0.80 [0.67-0.96] viral+ 991 (n) 3,952 (n) Pfizer (DB RCT) 37% 0.63 [0.40-1.00] cases 986 (n) 985 (n) Pfizer (DB RCT) 32% 0.68 [0.46-1.00] cases 986 (n) 985 (n) paxlovid COVID-19 outcomes c19early.com/pl May 2022 Favors paxlovid Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit